[Subcortical vascular encephalopathy].
Subcortical Vascular Encephalopathy (SVE) is an increasingly diagnosed disease with an enormous socio-economic impact. SVE leads to a progressive disability with immobilisation because of gait- and postural disturbances and with a progressive subcortical vascular dementia which is composed of cognitive slowing, loss of initiative and forgetfulness. A valid diagnosis has become possible only through a clear improvement in cerebral imaging techniques developed in the eighties. This explains, why so many different and confusing terms exist to describe the syndrome. The pathophysiological basis is a cerebral microangiopathy leading to lacunar infarcts and to diffuse ischemic white matter lesions, often occurring side by side. Taken together, such lesions lead to an interruption of parallel functional prefrontal-subcortical circuits, which are essential for psychomotor function. Neuroradiological methods like computed tomography (CT) and magnetic resonance imaging (MRI) are essential for the diagnosis. The prognosis is rather unfavourable. Several consensus meetings have established clinical and diagnostic criteria, which can serve as a basis for therapeutical trials. This review delineates diagnostic milestones, discusses etiological and pathophysiological mechanisms, and displays therapeutical options.
Baezner
H
H
Neurologische Universitätsklinik, Klinikum Mannheim, Ruprecht-Karls-Universität Heidelberg, Mannheim. baezner@neuro.ma.uni-heidelberg.de
Daffertshofer
M
M
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015140:Dementia, Vascular / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology; D003937:Diagnosis, Differential; D000077265:Donepezil; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005684:Gait; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D048448:Phenylcarbamates; D010865:Pilot Projects; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011379:Prognosis; D012307:Risk Factors; D000068836:Rivastigmine; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016138:Walking
D002219:Carbamates; D015259:Dopamine Agents; D007189:Indans; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D010919:Placebos; D000077265:Donepezil; D000547:Amantadine; D000068836:Rivastigmine